Loading…
Employees: 109
Size Janux Therapeutics (JANX) is a United States Health Care company (Biotechnology) with a market value of $1.08B, the 2201st largest of 3,117 United States companies the cockpit tracks. Shares closed at $17.63 on 6 Nov 2026.
Performance Over six months the shares gained 24.4%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 5,367.0% over the last twelve months (peer median +0.2%); the operating margin is -598.1% (peer median -55.1%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 9.2× (6th cheapest of 15).
Short interest Short interest is 8.7% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $24.0M | $10.0M | $10.6M | $8.08M | $8.61M |
| Revenue growth | — | -6% | +31% | -6% | — |
| Gross profit | $22.1M | $7.97M | $8.53M | $6.13M | $7.77M |
| EBITDA | -$142M | -$156M | -$96.8M | -$71.0M | -$66.2M |
| Net income | -$103M | -$114M | -$69.0M | -$58.3M | -$63.1M |
| Free cash flow | -$41.9M | -$83.3M | -$44.2M | -$52.4M | -$49.4M |
| Capital expenditure | $674,000 | $1.04M | $359,000 | $1.85M | $6.45M |
| Total debt | $21.0M | $22.1M | $23.0M | $24.5M | $25.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JANX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.7% | -5.6% | 10th highest of 21 |
| 6-month return | +24.4% | -10.9% | 4th highest of 20 |
| Distance from 52-week high | -50.1% | -36.7% | 5th lowest of 21 |
| Revenue growth (TTM) | +5,367.0% | +0.2% | highest of 14 |
| Operating margin | -598.1% | -55.1% | 4th lowest of 15 |
| EV / Sales | 5.3× | 9.2× | 6th cheapest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |